2 results
Approved WMOCompleted
To prove superiority of Fermathron plus in the treatment of patients with mild knee OA compared to placebo
Approved WMOCompleted
Primary Objective* To evaluate the antitumor efficacy of PO single agent CO-1686, as measured by ORR, when administered to patients with EGFR mutated, centrally confirmed T790M positive and T790M negative advanced NSCLC after tumor progression on 1…